Close Menu

gene expression analysis

The company hopes to use proceeds from the stock offering to support the commercial launch of its Digital Spatial Profiling platform next year.

Unicancer will provide patients with centralized laboratory testing performed by Agendia, and also adopt the company's NGS kits for decentralized testing.

The company plans to commercialize a gene expression signature to predict recurrence risk in cutaneous squamous cell carcinoma.

The company's net loss climbed about 30 percent to $4.0 million for Q4 2017, and reached $19.4 million for the full year.

The company plans to launch an RNA sequencing-based test to help subtype and determine treatment for thyroid cancer, and a test to detect noninvasive lung cancer.

The genomic testing firm beat the consensus top line estimates by reporting Q4 2017 revenues of $19.6 million and full-year 2017 revenues of $72.0 million.

An assessment concluded that Oncotype Dx has not demonstrated a significant enough impact on outcomes or cost effectiveness compared to current practice.

Veracyte attributed its lower Afirma sales in part to slowing down the rollout of an updated version of the test that relies on RNA sequencing.

The genomic testing company's total revenues were down to $17.5 million in the quarter, although its genomic testing volume increased 14 percent.

The company said that more than 95 percent of eligible early-stage breast cancer patients can now have the test paid by insurance.

Pages